Similar articles

• Clinical study of a new anti-inflammatory drug: 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370).

  Dotti F, Ongari R, Carazzi R, Chierichetti S. Dotti F, et al. Arzneimittelforschung. 1972 Jan;22(1):Suppl 1a:265-8. Arzneimittelforschung. 1972. PMID: 4553235 Clinical Trial. No abstract available.
• Metabolic and clinical effects of 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370).

  Ghiringhelli F, Mazzi C, Chierichetti S. Ghiringhelli F, et al. Arzneimittelforschung. 1972 Jan;22(1):Suppl 1a:268-7. Arzneimittelforschung. 1972. PMID: 5067203 No abstract available.
• Controlled clinical trial of 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370) and oxyphenbutazone in thrombophlebitis.

  Seghezzi R, Borri P, Chierichetti S, Ferrari P. Seghezzi R, et al. Arzneimittelforschung. 1972 Jan;22(1):Suppl 1a:272-4. Arzneimittelforschung. 1972. PMID: 4553236 Clinical Trial. No abstract available.
• Clinical and laboratory evaluation of 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370) in rheumatoid arthritis and ankylosing spondylitis.

  Lignière GC, Colombo B, Carrabba M, Ferrari P, Robotti E. Lignière GC, et al. Arzneimittelforschung. 1972 Jan;22(1):Suppl 1a:253-8. Arzneimittelforschung. 1972. PMID: 4553232 Clinical Trial. No abstract available.
• Methods of clinical assessment of anti-rheumatic drugs.

  Bellamy N. Bellamy N. Baillieres Clin Rheumatol. 1988 Aug;2(2):339-62. doi: 10.1016/s0950-3579(88)80018-9. Baillieres Clin Rheumatol. 1988. PMID: 3066498 Review. No abstract available.